ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ -- Integrated Biotherapeutics Inc. announced today that is has been awarded up to $168,000, with the possibility of up to $8.3 million more based on the achievement of milestones, to develop the first entirely toxoid-based multivalent vaccine for the prevention of Methicillin Resistant Staphylococcus Aureus (MRSA).
"The CARB-X award will help us complete the preclinical studies and the Phase I clinical trial for IBT-V02, the first entirely toxoid based multivalent vaccine for the prevention of infections with Staph Aureus," said Dr. M Javad Aman, President and Chief Scientific Officer of Integrated Biotherapeutics. "Antibiotic resistant Staph Aureus is a major public health threat causing numerous cases of invasive disease with high mortality rates in the hospitals and communities across the globe and billions of dollars in healthcare costs."
Staphylococcus Aureus causes serious diseases including blood stream infection, sepsis, endocarditis, surgical site infections, and pneumonia. Methicillin resistant Staph Aureus (MRSA) is currently a leading cause of these life-threatening infections with limited options for treatment.
IBT-V02 consists of five components representing toxoids for seven Staphylococcus Aureus toxins. Due to cross reactivity, these toxoids will elicit a protective response to 12-13 Staph Aureus toxins.
CARB-X, which stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, was launched in July 2016. This will be the first vaccine project for CARB-X.
"This is the first potential vaccine in the CARB-X portfolio, adding to the rich diversity of the pipeline and bringing a novel approach that could potentially prevent drug-resistant infection and save lives," said Kevin Outterson, Executive Director of CARB-X, the world's leading non-profit partnership dedicated to accelerating the development of antibiotics, diagnostics and other products to treat deadly infections caused by superbugs. "The projects in the new Powered by CARB-X portfolio are in the early stages of research, and there is always a high risk of failure. But if successful, these projects hold exciting potential in the fight against the deadliest drug-resistant bacteria."
About Integrated Biotherapeutics: IBT is a biotechnology company focused on the discovery of novel vaccines and therapies for emerging infectious diseases with a pipeline that includes promising product candidates for bacterial and viral infections including vaccines for Staphylococcal infections, unique pan-filovirus immunotherapeutics and vaccines, and a variety of other product candidates for emerging pathogens. Located in Rockville, MD, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH). National Cancer Research Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infection Diseases (USAMRIID) as well as many biotechnology and pharmaceutical companies and academic laboratories. For more information, visit www.integratedbiotherapeutics.com.
CARB-X is the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X will spend up to $455 million from 2016-2021 to support innovative antibiotics, vaccines and rapid diagnostics from 'hit-to-lead' stage through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is led by Boston University. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit www.carb-x.org and follow us on Twitter @CARB_X.
Robert Blackwell III
SOURCE Integrated Biotherapeutics Inc.